Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis

BackgroundAdipose-derived stem cell (ADSC) transplantation presents a promising approach for osteoporosis (OP) treatment. However, the therapeutic efficacy of ADSCs is hindered by low post-transplantation survival rates and limited capacities for adhesion, migration, and differentiation. Icariin (IC...

Full description

Saved in:
Bibliographic Details
Main Authors: Shaozi Lin, Zuyu Meng, Mei Wang, Zixuan Ye, Mengsha Long, Yiyao Zhang, Fang Liu, Hongling Chen, Menghan Li, Jiajia Qin, Haiquan Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1510561/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841543642840301568
author Shaozi Lin
Zuyu Meng
Mei Wang
Zixuan Ye
Mengsha Long
Yiyao Zhang
Fang Liu
Hongling Chen
Menghan Li
Jiajia Qin
Haiquan Liu
author_facet Shaozi Lin
Zuyu Meng
Mei Wang
Zixuan Ye
Mengsha Long
Yiyao Zhang
Fang Liu
Hongling Chen
Menghan Li
Jiajia Qin
Haiquan Liu
author_sort Shaozi Lin
collection DOAJ
description BackgroundAdipose-derived stem cell (ADSC) transplantation presents a promising approach for osteoporosis (OP) treatment. However, the therapeutic efficacy of ADSCs is hindered by low post-transplantation survival rates and limited capacities for adhesion, migration, and differentiation. Icariin (ICA), the primary active compound of Epimedium, has been shown to promote cell proliferation and induce osteogenic differentiation; however, its specific effects on ADSC osteogenesis and the mechanisms by which ICA enhances osteoporosis treatment through cell transplantation remain inadequately understood.PurposeThis study investigates the effects of different concentrations of ICA on the osteogenic and adipogenic differentiation of rat ADSCs, aiming to elucidate the underlying mechanisms. ADSCs were isolated from female SPF-grade SD rats, with surface markers identified through flow cytometry. Osteogenic and adipogenic differentiation were assessed using Alizarin Red and Oil Red O staining, respectively. Third-generation ADSCs were divided into five groups: control, resveratrol (100 μmol/L), and four ICA treatment groups (1, 10, 50, and 100 μmol/L). Western blotting was performed to analyze the expression of factors associated with the Hippo-YAP/TAZ signaling pathway and the adipogenic marker PPARγ. Additionally, ADSCs were labeled with lentiviruses carrying enhanced green fluorescent protein (EGFP) and 5-bromo-2-deoxyuridine (BrdU) to assess their in vivo distribution, survival, proliferation, and differentiation of ADSCs post-ICA intervention.ResultsIn vitro, ICA significantly inhibited the Hippo pathway, reducing YAP and TAZ phosphorylation and enhancing their transcriptional activity, while simultaneously suppressing PPARγ. This promoted osteogenesis and inhibited adipogenesis in ADSCs. In vivo, ICA-treated ADSCs demonstrated effective distribution, survival, and osteogenic differentiation following subcutaneous injection into allogeneic rats.ConclusionOur study demonstrates that ICA significantly enhances the osteogenic differentiation of ADSCs while inhibiting adipogenesis, providing novel insights and therapeutic strategies for osteoporosis and related conditions.
format Article
id doaj-art-c9bc25d017b34f4b979f6c4e3e0f159b
institution Kabale University
issn 1663-9812
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-c9bc25d017b34f4b979f6c4e3e0f159b2025-01-13T09:24:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15105611510561Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosisShaozi Lin0Zuyu Meng1Mei Wang2Zixuan Ye3Mengsha Long4Yiyao Zhang5Fang Liu6Hongling Chen7Menghan Li8Jiajia Qin9Haiquan Liu10School of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaHuizhou Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, ChinaHuizhou Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, ChinaBackgroundAdipose-derived stem cell (ADSC) transplantation presents a promising approach for osteoporosis (OP) treatment. However, the therapeutic efficacy of ADSCs is hindered by low post-transplantation survival rates and limited capacities for adhesion, migration, and differentiation. Icariin (ICA), the primary active compound of Epimedium, has been shown to promote cell proliferation and induce osteogenic differentiation; however, its specific effects on ADSC osteogenesis and the mechanisms by which ICA enhances osteoporosis treatment through cell transplantation remain inadequately understood.PurposeThis study investigates the effects of different concentrations of ICA on the osteogenic and adipogenic differentiation of rat ADSCs, aiming to elucidate the underlying mechanisms. ADSCs were isolated from female SPF-grade SD rats, with surface markers identified through flow cytometry. Osteogenic and adipogenic differentiation were assessed using Alizarin Red and Oil Red O staining, respectively. Third-generation ADSCs were divided into five groups: control, resveratrol (100 μmol/L), and four ICA treatment groups (1, 10, 50, and 100 μmol/L). Western blotting was performed to analyze the expression of factors associated with the Hippo-YAP/TAZ signaling pathway and the adipogenic marker PPARγ. Additionally, ADSCs were labeled with lentiviruses carrying enhanced green fluorescent protein (EGFP) and 5-bromo-2-deoxyuridine (BrdU) to assess their in vivo distribution, survival, proliferation, and differentiation of ADSCs post-ICA intervention.ResultsIn vitro, ICA significantly inhibited the Hippo pathway, reducing YAP and TAZ phosphorylation and enhancing their transcriptional activity, while simultaneously suppressing PPARγ. This promoted osteogenesis and inhibited adipogenesis in ADSCs. In vivo, ICA-treated ADSCs demonstrated effective distribution, survival, and osteogenic differentiation following subcutaneous injection into allogeneic rats.ConclusionOur study demonstrates that ICA significantly enhances the osteogenic differentiation of ADSCs while inhibiting adipogenesis, providing novel insights and therapeutic strategies for osteoporosis and related conditions.https://www.frontiersin.org/articles/10.3389/fphar.2024.1510561/fullIcariinadipose-derived stem cellsHIPPO-YAP/TAZosteogenicadipogenesis
spellingShingle Shaozi Lin
Zuyu Meng
Mei Wang
Zixuan Ye
Mengsha Long
Yiyao Zhang
Fang Liu
Hongling Chen
Menghan Li
Jiajia Qin
Haiquan Liu
Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis
Frontiers in Pharmacology
Icariin
adipose-derived stem cells
HIPPO-YAP/TAZ
osteogenic
adipogenesis
title Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis
title_full Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis
title_fullStr Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis
title_full_unstemmed Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis
title_short Icariin modulates osteogenic and adipogenic differentiation in ADSCs via the Hippo-YAP/TAZ pathway: a novel therapeutic strategy for osteoporosis
title_sort icariin modulates osteogenic and adipogenic differentiation in adscs via the hippo yap taz pathway a novel therapeutic strategy for osteoporosis
topic Icariin
adipose-derived stem cells
HIPPO-YAP/TAZ
osteogenic
adipogenesis
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1510561/full
work_keys_str_mv AT shaozilin icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT zuyumeng icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT meiwang icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT zixuanye icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT mengshalong icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT yiyaozhang icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT fangliu icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT honglingchen icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT menghanli icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT jiajiaqin icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis
AT haiquanliu icariinmodulatesosteogenicandadipogenicdifferentiationinadscsviathehippoyaptazpathwayanoveltherapeuticstrategyforosteoporosis